Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713300 | 1.00 | KMT2A (0.40) | KMT2AMAPTCACNA1BAPBA1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6347037 | 0.98 | KMT2A (0.39) | KMT2AMAPTCACNA1BAPBA1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6347040 | 0.98 | KMT2A (0.39) | KMT2AMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL423892 | 0.90 | KMT2A (0.47) | KMT2AMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL719931 | 0.90 | — | — | |
| SCHEMBL11769670 | 0.83 | KMT2A (0.41) | KMT2AMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL1219520 | 0.83 | KMT2A (0.41) | KMT2AMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL6350238 | 0.82 | ALDH1A1 (0.44) | KMT2AMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL7133197 | 0.82 | ALDH1A1 (0.41) | KMT2AMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL7371774 | 0.82 | PLG (0.48) | KMT2AMAPTCACNA1BAPBA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| CN-109069512-B | Substituted aminopurine compounds, compositions thereof, and related methods of treatment | 西格诺药品有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-113248506-A | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3822274-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210128565-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-05-06 | — | — | US | disclosed |
| CN-107001372-B | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2021-04-27 | — | — | CN | disclosed |
| US-10940152-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3204386-B1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| JP-2004352654-A | METHOD FOR SEPARATING CIS/TRANS ISOMER MIXTURE OF 4-AMINOCYCLOHEXANECARBOXYLIC ACID ALKYL ESTER | NEW JAPAN CHEM CO LTD | 2004-12-16 | — | — | JP | disclosed |
| US-20040229926-A1 | Aliphatic nitrogen - containing 5 - membered ring compound | TANABE SEIYAKU CO., LTD. | 2004-11-18 | — | — | US | disclosed |
| EP-1476158-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040063935-A1 | Aliphatic nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003068233-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068235-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-1325910-A1 | ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063935-A1 | Aliphatic nitrogenous five-membered ring compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SCN5A, CYP11B1 | KMT2A 3485/4885MAPT 2836/4885CACNA1B 1127/4885 |
| US-10940152-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | KMT2A 382/4885MAPT 1464/4885CACNA1B 4668/4885 |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | KMT2A 382/4885MAPT 1464/4885CACNA1B 4668/4885 |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | NNT, IL5, NOX5 | KMT2A 2623/4885MAPT 2477/4885CACNA1B 495/4885 |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | KMT2A 2770/4885MAPT 3723/4885CACNA1B 2969/4885 |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | KMT2A 2770/4885MAPT 3723/4885CACNA1B 2969/4885 |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | KMT2A 382/4885MAPT 1464/4885CACNA1B 4668/4885 |
| US-20210128565-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | KMT2A 382/4885MAPT 1464/4885CACNA1B 4668/4885 |
| US-20040229926-A1 | Aliphatic nitrogen - containing 5 - membered ring compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1, CYP11B2 | KMT2A 2980/4885MAPT 3375/4885CACNA1B 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.